Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Avelumab in combinations for lung cancer and update from ALEX study

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 989

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Dr Shaw speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about results from the JAVELIN 101 trial of avelumab in combination with either criztonib or lorlatinib

She reports low efficacy and limiting toxicities in the crizotinib arm, whereas lorlatinib was better tolerated and more efficacious.

Dr Shaw also presents updates from the ALEX trial of alectinib, with longer follow up and a median PFS now available, and considers its role in future trials and combinations.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation